Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 2/3/2026 | $26.00 | Neutral | Wedbush | |
| 1/16/2026 | $13.00 | Underweight | Morgan Stanley | |
| 9/5/2025 | $74.00 | Neutral | Robert W. Baird | |
| 5/15/2025 | $112.00 | Buy | Tigress Financial | |
| 4/21/2025 | $17.00 | Equal Weight | Wells Fargo | |
| 2/12/2025 | Buy → Hold | Jefferies | ||
| 2/12/2025 | $45.00 → $17.00 | Outperform → Neutral | Mizuho | |
| 2/12/2025 | Buy → Neutral | BTIG Research |
Wedbush initiated coverage of STAAR Surgical with a rating of Neutral and set a new price target of $26.00
Morgan Stanley resumed coverage of STAAR Surgical with a rating of Underweight and set a new price target of $13.00
Robert W. Baird initiated coverage of Dolby Labs with a rating of Neutral and set a new price target of $74.00
3 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - Dolby Laboratories, Inc. (0001308547) (Issuer)
4 - Dolby Laboratories, Inc. (0001308547) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
CHICAGO, Feb. 3, 2026 /PRNewswire/ -- Today, Source Elements announced that Source-Connect 4 has become the industry's first remote collaboration solution to achieve Dolby Atmos certification with metadata connection to the Dolby Atmos Renderer. With 128 audio streaming channels supporting any combination of beds and objects—plus full metadata integration—the update connects immersive environments like never before. Mixers, directors, and stakeholders can now attend Dolby Atmos playback and mixing sessions from their preferred location or setup, unlocking new possibilities for remote collaboration.
Search Committee Has Initiated a Global Search to Select Next CEO STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors (the "Board") has appointed Warren Foust, President and Chief Operating Officer, and Deborah Andrews, Chief Financial Officer, as interim co-Chief Executive Officers, effective February 1, 2026. Mr. Foust and Ms. Andrews will work together with the other members of the executive leadership team, with support and guidance from the Board, as they lead the Company and manage its day-to-day operations.
SAN FRANCISCO, Jan. 29, 2026 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the first quarter of fiscal 2026. "With a good start to the fiscal year, we are optimistic about our position in the market and confident in our growth opportunities," said Kevin Yeaman, President and CEO, Dolby Laboratories. "We continue to have strong momentum with Dolby Atmos and Dolby Vision, while also expanding our addressable market with our imaging patent program for content streamers and Dolby OptiView." First Quarter Fiscal 2026 Financi
SCHEDULE 13G/A - Dolby Laboratories, Inc. (0001308547) (Subject)
8-K - Dolby Laboratories, Inc. (0001308547) (Filer)
8-K - STAAR SURGICAL CO (0000718937) (Filer)
Search Committee Has Initiated a Global Search to Select Next CEO STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors (the "Board") has appointed Warren Foust, President and Chief Operating Officer, and Deborah Andrews, Chief Financial Officer, as interim co-Chief Executive Officers, effective February 1, 2026. Mr. Foust and Ms. Andrews will work together with the other members of the executive leadership team, with support and guidance from the Board, as they lead the Company and manage its day-to-day operations.
Neal Bradsher and Richard LeBuhn of Broadwood and Christopher Wang of Yunqi Capital have Joined STAAR Board STAAR Chair Elizabeth Yeu and CEO Stephen Farrell have Stepped Down from the Board Farrell will Remain CEO until January 31, 2026 STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, and Broadwood Partners, L.P. and its affiliates ("Broadwood"), which together own 31% of STAAR's outstanding common stock, today announced that Neal C. Bradsher and Richard T. LeBuhn of Broadwood and Christopher Wang of Yunqi Capital, which with its affiliates owns 6.5%
Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC). Neal C. Bradsher, Founder and President of Broadwood, said: "For more than three months, we have been telling the Board of Directors tha
SAN FRANCISCO, Jan. 29, 2026 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the first quarter of fiscal 2026. "With a good start to the fiscal year, we are optimistic about our position in the market and confident in our growth opportunities," said Kevin Yeaman, President and CEO, Dolby Laboratories. "We continue to have strong momentum with Dolby Atmos and Dolby Vision, while also expanding our addressable market with our imaging patent program for content streamers and Dolby OptiView." First Quarter Fiscal 2026 Financi
SAN FRANCISCO, Jan. 13, 2026 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE:DLB), a leader in immersive entertainment experiences, will release financial results for the first quarter (Q1) fiscal year 2026 after the close of regular trading on Thursday, January 29, 2026. Members of Dolby management will lead a conference call open to all interested parties to discuss Q1 fiscal year 2026 financial results for Dolby Laboratories at 2:00 p.m. PT (5:00 p.m. ET) on Thursday, January 29, 2026. Access to the teleconference will be available at http://investor.dolby.com or by dialing
SAN FRANCISCO, Nov. 18, 2025 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the fourth quarter and fiscal year 2025. "We finished FY25 strong, growing Dolby Atmos, Dolby Vision and imaging patents, and expanding our addressable market with momentum in Dolby OptiView and the introduction of a new imaging patent pool for content streamers," said Kevin Yeaman, President and CEO, Dolby Laboratories. "As we head into FY26, I'm confident in our strategy to grow our business by delivering value across current and future ecosyst
SC 13G/A - Dolby Laboratories, Inc. (0001308547) (Subject)
SC 13G/A - Dolby Laboratories, Inc. (0001308547) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)